癌症免疫疗法市场成长机会（2024-2030）

下一代免疫疗法、人工智慧和生物标誌物驱动的个人化治疗进步将推动转型成长

全球癌症发生率预计将从2022年的2,000万例增加77%，到2050年将超过3,500万例。饮酒、吸烟、肥胖和空气污染是导致癌症发生率上升的主要原因。现今的癌症研究重点是细胞和基因治疗、抗体药物复合体(ADC)、查核点抑制剂和多特异性抗体。临床试验主要集中于放射线治疗、化疗和多种免疫疗法药物的组合，目前有超过5000种癌症免疫疗法正在开发中。

免疫肿瘤学 (IO) 彻底改变了癌症治疗，但必须应对临床试验挑战，以改善患者预后并加快核准。许多免疫肿瘤学疗法在规模过大或患者群体不匹配的情况下进行评估，最终失败。人体免疫反应并非总是能够透过动物模型或二维体外系统预测。传统的随机对照试验无法检测出药物未达到预期疗效的征兆，也不需要持续调整药物。

人工智慧和生物标记指导的患者选择、抵消抗药性的联合疗法、免疫相关不利事件的即时安全监测、改善患者可及性的分散式临床试验以及自适应的人工智慧主导的试验设计是应对这些挑战的基本策略。这些方法使相关人员能够增强肿瘤免疫疗法创新，并提高癌症治疗的有效性、可近性和安全性。

改良的生物标记平台有助于提升我们对肿瘤免疫生物学认知的深度和精准度。生物标记研究的快速发展领域包括多重免疫组化 (IHC)、基于NGS的基因突变和表现图谱检测、高阶基因结构的表观遗传图谱绘製以及肿瘤能量状态的代谢谱分析。

本研究检视了临床和管道发展、技术创新和区域市场动态，以概述 2025 年至 2030 年全球 IO 市场和收益预测。地理覆盖范围包括北美、欧洲、亚太、中东和北非以及拉丁美洲。

本研究检验了推动免疫治疗发展的关键主题和技术，重点关注查核点抑制剂、抗体偶联药物 (ADC)、双特异性抗体、癌症疫苗以及过继性细胞疗法，包括 CAR-T、TCR 和 TIL。研究重点关注策略目标领域，包括克服对 PD-1/PD-L1 抑制剂的抗药性，以及下一代药物，包括同种异体疗法和特异性治疗方法。在这种动态环境中，本研究也探讨了成长驱动因素、阻碍因素以及相关人员的机会。

收益及预测

预计 2024 年营收将达到 1,106.9 亿美元，在 2021 年至 2030 年的研究期间内，年复合成长率（CAGR）为 10.7%。

三大战略要务对生医治疗产业的影响

压缩客户价值链

为什么

压迫免疫肿瘤学市场的价值链意味着优化和简化患者的诊疗过程，包括诊断、治疗和术后护理。这可以透过整合各种医疗服务并利用免疫肿瘤学临床试验市场的尖端技术来实现。

全面全面的癌症治疗非常重要，特别是在市场脉络，包括综合治疗设施、协调的护理团队和广泛的后续护理计划。

观点

免疫肿瘤学市场的公司正在提供直接面向消费者的服务，例如家用癌症风险基因检测套组，以加速诊断过程。

数位技术在自适应、人工智慧主导的癌症临床试验市场脉络优化营运、提高病人参与并客製化护理，包括远端咨询、数据驱动的诊断和治疗建议。

透过将种族、年龄和社会经济因素紧密结合到生存和临床决策中，肿瘤学价值链可以显着改善免疫肿瘤生物标记平台市场的患者体验。

颠覆性技术

为什么

最近的技术进步，包括单细胞定序和空间转录组学，大大增强了我们对肿瘤微环境免疫生物学的理解，影响了自适应人工智慧驱动的癌症临床试验市场。

一种新的人工智慧方法利用治疗变化预测来识别临床试验候选者，并推动了次世代定序仪(NGS) 数据在下一代免疫肿瘤学市场中用于患者试验匹配的应用。一种机器学习演算法利用患者报告的结果变数来预测急性癌症治疗的发生率。

赛诺菲正在与 Owkin 合作，以加强生物标记识别并提高临床试验的成功率，而葛兰素史克则与 Tempus 合作，以支持其在免疫肿瘤学市场的努力。

观点

多重模式方法增进了我们对与免疫肿瘤学市场相关的肿瘤-免疫系统交互作用的理解。数位化工具有助于组织数据、揭示复杂模式并灵活提取免疫学相关资讯。由于致力于免疫疗法创新的公司寥寥无几，因此选择至关重要。

人工智慧和加速运算正在彻底改变医疗保健，NVIDIA 等公司大力投资医疗保健服务，包括 IOVIA、Illumina 和 Mayo Clinic，影响着自适应人工智慧主导的癌症临床试验市场。

竞争激烈程度

为什么

免疫肿瘤学市场竞争激烈，多家公司追求类似的临床目标，大型製药公司与新兴生物技术公司合作，在免疫肿瘤学临床试验市场中寻求新资产。

随着免疫疗法、放射线治疗、标靶治疗和微生物组调节等新兴需求的融合，临床开发和法规环境变得更加复杂。

免疫肿瘤生物标记平台市场在细胞疗法、肿瘤病毒、mRNA 疫苗和人工智慧生物标记发现方面取得了进展，推动了许多策略合作伙伴关係、合资企业、合併和收购。

观点

儘管近年来取得了一些突破，但癌症免疫疗法领域在临床试验市场中仍面临诸多障碍，包括疗效有限、疗效持续时间短暂以及副作用意外等。一种常见的策略是专注于透过精准标靶药物应用于特定的患者群体和肿瘤类型，从而实现差异化。

影响因素：人类正在推动公司透过RWE优化其品牌扩大策略。市场RWE推动早期小细胞肺疾病的退出。

驱动程式

• 生物标记平台的技术发展有望提供更准确、更全面的肿瘤免疫生物学知识。多种免疫组化 (IHC) 技术、基于 NGS 的检测（用于检测基因突变和基因表现谱）、表观遗传图谱（用于定义高阶遗传结构）以及代谢谱（用于评估肿瘤能量状态）是癌症免疫学市场中生物标记研究的快速发展领域。结合这些方法可以提供全面、多方面的肿瘤资讯。例如，将多种免疫组化 (IHC) 技术、成像技术与 NGS 技术相结合，可以揭示肿瘤内细胞间相互作用背景下基因表现的空间分布。
• 抗PD-(L)1和抗CTLA-4免疫疗法已经改变了免疫肿瘤学市场的癌症治疗，但抗药性和毒性仍然存在。随着免疫治疗领域的进步，新的免疫调节标靶和机制被发现，有望增强治疗性免疫疗法。随着人们对癌症免疫生物学的理解加深和抗体工程的进步，针对其他抑制性免疫查核点（例如LAG-3、TIM-3、TIGIT、CD47和B7家族）的药物在免疫肿瘤学研究中变得越来越重要。
• 免疫疗法和分子标靶疗法等精准医疗方法彻底改变了免疫肿瘤临床试验市场的癌症治疗。然而，只有一小部分患者受益于这些治疗方法。大多数癌症会对常规治疗产生抗药性。这些问题正透过结合各种治疗方法的临床研究得到解决。这些研究使用免疫疗法、分子标靶疗法和放射线治疗来治疗各种恶性肿瘤。新出现的证据表明，联合治疗可以预防或延缓抗药性。免疫疗法，尤其是 ICI，与其他癌症治疗方法合併使用时效果显着。 FDA核准的多项癌症治疗免疫疗法组合证明了下一代免疫肿瘤疗法的有效性。
• 癌症免疫学市场需要更广泛地采用创新工具，这些工具能够有效地测量和整合影响肿瘤免疫和免疫治疗反应的各种宿主因素。穿戴式装置可以追踪各种生理变量，包括心率、呼吸频率、氧合水平、睡眠模式以及压力和痛苦程度。评估全身性发炎和代谢健康的设备正在开发中或已上市。在自适应人工智慧主导的肿瘤临床试验市场中，已有工具可用于捕捉食物和其他代谢物的消耗，以说明代谢变数。已有技术可用于说明饮食模式并分析数据驱动的饮食模式与疗效之间的关联。

成长阻碍因素

• 阐明抗肿瘤反应、免疫相关毒性和治疗抗药性的机制面临三大挑战：用于正向和反向应用的临床相关肿瘤模型的可用性、从接受免疫治疗的患者身上收集的生物样本的可用性以便在基准、治疗期间和治疗后进行纵向分析，以及实施在免疫肿瘤学临床试验市场中进行研究的标准化定义和框架。
• 基因组检测有望在免疫肿瘤学市场提供宝贵的临床讯息，但也可能对个人和家庭产生经济和心理影响。它还可能导致社会耻辱感，并影响保险覆盖范围。由于需要快速检测和高效的数据分析，检测可能具有挑战性。临床追踪的另一个问题是，当发现新的生殖系致病变异并确定疾病的相对风险时，需要重新评估家庭和个人面临的风险。
• 在免疫肿瘤生物标记平台市场中，识别最合适的标靶抗原仍然是一项重大挑战。由病毒感染或基因突变（无论是遗传性或后天性）引起的肿瘤可能含有免疫系统易于辨识的（新）抗原。在其他情况下，常见的肿瘤抗原可能提供更广泛的适用治疗方法。在免疫肿瘤市场中，研究癌前病变以发现新的强效抗原至关重要。在肿瘤发生早期出现的病变，例如增生和原位癌，通常较小，只需有限的组织即可进行检查。取得这些病灶可能具有挑战性，取得组织样本可能需要由熟练的专家进行专门的操作，例如菌落细胞学检查或支气管镜检查。
• 在自适应人工智慧主导的癌症临床试验市场中，目前的临床前模型不足以重现宿主环境对癌症发生、进展和免疫反应的影响。这可能导致它们无法充分确定免疫疗法反应和抗药性机制以及免疫相关毒性。癌症免疫学市场需要能够有效捕捉复杂宿主-环境相互作用的新模型，这些相互作用在塑造肿瘤免疫系统动态中起着关键作用。例如，烟雾引起的基因破坏已被证明会改变癌症肿瘤的增强和发展。因此，在癌症免疫学临床试验市场中，基因组吸烟特征的存在，特别是由NGS发现并由TMB反映的吸烟相关基因改变，与其对癌症背景下免疫细胞行为的影响之间存在明显的相关性。关于间接环境暴露对肿瘤免疫和免疫疗法疗效的影响，仍有许多有待发现。

目录

调查范围

成长环境：癌症免疫治疗市场的转型

癌症免疫治疗市场生态系统

• 全球癌症病例和死亡人数
• 全球新增癌症病例预测
• 主要治疗类别
• 肿瘤药物研发趋势
• IO药物开发趋势
• 临床试验挑战及克服策略
• 癌症治疗的技术趋势
• IO经营模式
• 策略伙伴关係与合作 - ICI
• 策略伙伴关係与合作 - ACT
• 策略伙伴关係与合作－基于抗体的标靶治疗
• 策略伙伴关係与合作 - 癌症疫苗
• 推进精准肿瘤学的关键策略
• 併购估值
• 创投估值
• 竞争环境
• 主要竞争对手：IO价值链与相关利益者生态系统

推动IO治疗市场成长的因素

• 成长指标
• 成长动力
• 成长限制因素
• 研究过程和调查方法
• 预测考虑因素
• 收益预测
• 收益预测分析
• 按模式分類的收益预测
• 收益预测分析
• 按指标预测收益
• 收益预测分析
• 各地区收益预测
• 区域预测分析
• 趋势与措施 - 北美
• 趋势与倡议 - 欧洲
• 亚太地区趋势与倡议
• 趋势与措施 - 拉丁美洲
• 趋势与倡议—中东和北非
• IO 定价趋势和降低成本的潜在途径
• 中低收入国家癌症免疫治疗的成本降低策略
• 收益分享
• 收益份额分析

成长动力：ICI

• 成长指标
• 收益预测
• 预测分析

成长动力：ACT

• 成长指标
• 收益预测
• 预测分析

增长动力：基于抗体的标靶治疗

• 成长指标
• 收益预测
• 收益预测-ADC

成长动力：其他

• 成长指标
• 收益预测
• 预测分析

成长机会

• 成长机会1：扩大免疫查核点ICI在早期癌症术前和术后治疗的应用
• 成长机会2：不断发展的多生物标记方法
• 成长机会3：准确模拟肿瘤免疫生物学的临床前模型
• 成长机会4：基于生成式人工智慧的电脑In Silico技术

后续步骤Next steps

Advances in Next-Generation Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific antibodies. With clinical trials emphasizing combinations of radiation, chemotherapy, or many immunotherapy medicines, more than 5,000 immuno-oncology medications are under development.

Although immuno-oncology (I-O) has revolutionized cancer therapy, problems with clinical trials must be resolved to improve patient outcomes and speed approvals. Many I-O therapies show failure when evaluated across too-large or incompatible patient groups; human immune responses cannot always be deduced from animal models and two-dimensional in vitro systems. Conventional randomized controlled studies may not find signs or call for continuous changes should a medicine not be functioning as expected.

AI and biomarker-based patient selection, combination approaches to offset resistance, real-time safety monitoring for immune-related adverse events, distributed clinical trials to improve patient access, and adaptive, AI-driven trial designs are fundamental strategies to meet these challenges. With these approaches, stakeholders are strengthening I-O innovation and improving the effectiveness, accessibility, and safety criteria of cancer therapy.

Improved biomarker platforms help to increase tumor immunobiology's depth of knowledge and accuracy. Fast-growing fields in biomarker research include multiplex IHC, NGS-based testing for gene mutations and expression profiles, epigenetic mapping for higher-order gene structures, and metabolic profiling for tumor energy status.

Frost & Sullivan studied clinical and pipeline developments, technological innovation, and regional market dynamics to develop this research service, which provides an overview of the global I-O market and a revenue projection from 2025 to 2030. The geographical scope is North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America.

With an eye on checkpoint inhibitors, ADC, bispecific antibodies, cancer vaccines, and adoptive cell treatments including CAR-T, TCR, and TILs, this report examines the main themes and technologies driving the evolution of I-O therapies. Along with strategic target areas including overcoming resistance to PD-1/PD-L1 inhibitors, it stresses next-generation drugs including allogeneic approaches and multi-specific modalities. In this fast-changing environment, the study also investigates growth drivers, restraints, and opportunities for stakeholders.

Revenue Forecast

The revenue estimate for the base year 2024 is projected at $110.69 billion, with a compound annual growth rate (CAGR) of 10.7% during the study period from 2021 to 2030.

The Impact of the Top 3 Strategic Imperatives on the I-O Therapeutics Industry

Customer Value Chain Compression

Why

Patient value chain compression in the immuno-oncology market entails optimizing and simplifying the patient's journey, including the stages of diagnosis, treatment, and post-treatment care. This is accomplished by combining different healthcare services and using cutting-edge technology in immuno-oncology clinical trials market.

Comprehensive, integrated cancer care is important, especially in the context of the immuno-oncology biomarker platforms market. Integrated treatment facilities, coordinated care teams, and extensive aftercare plans are examples of this.

Frost Perspective

Companies in the immuno-oncology market are providing direct-to-consumer services, such as cancer risk genetic testing kits that may be used at home thus expedite the diagnosing process.

Digital technology optimizes operations, improves patient engagement, and customizes treatment in the context of the adaptive AI-driven oncology trials market. This includes remote consultations, data-driven diagnostics, and treatment recommendations.

By tightly integrating racial, age, and socioeconomic considerations into their survival and clinical decision-making, the oncology value chain can significantly improve patients' experiences within the immuno-oncology biomarker platforms market.

Disruptive Technologies

Why

Recent technological advancements, including single-cell sequencing and spatial transcriptomics, have greatly enhanced our understanding of the immunobiology of the tumor microenvironment, influencing the adaptive AI-driven oncology trials market.

A new AI method uses treatment change predictions to identify clinical trial candidates, advancing the use of next-generation sequencing (NGS) data for patients' trial matching in the next-generation immuno-oncology therapies market. A machine learning algorithm predicts cancer acute care occurrences using patient-reported outcome variables.

Sanofi is collaborating with Owkin to boost biomarker identification and raise clinical trial success rates. GSK has teamed with Tempus to aid the effort in the immuno-oncology market.

Frost Perspective

Multi-modality methods have improved our understanding of tumor-immune system interactions relevant to the immuno-oncology market. Digital tools help to organize data, uncover complicated patterns, and extract immunologically relevant information in a flexible way. Since few companies respond to innovations in immunotherapy, it is crucial to select.

AI and accelerated computing are revolutionizing medicine, and companies like NVIDIA are investing heavily in healthcare services, including IOVIA, Illumina, and Mayo Clinic, impacting the adaptive AI-driven oncology trials market.

Competitive Intensity

Why

The immuno-oncology market is competitive, with several companies aiming for similar clinical targets and big pharma teaming up with emerging biotech for novel assets in the immuno-oncology clinical trials market.

Clinical development and regulatory environments are complicated by the convergence of immunotherapy, radiation, targeted treatments, and new demands, such as microbiome regulation.

Cell treatments, oncologic viruses, mRNA vaccines, and AI-driven biomarker discovery are advancing in the immuno-oncology biomarker platforms market. These developments have driven many strategic alliances, joint ventures, mergers, and acquisitions.

Frost Perspective

Despite recent breakthroughs, there are still obstacles in the field of cancer immunotherapy within the immuno-oncology clinical trials market. These include limited effectiveness, temporary duration, and unintended impacts. Under a general strategy, differentiating via precision targets medicines for certain patient groups or tumor types has become a focal point.

Factors: Human beings are asking companies to optimize label expansion strategies via RWE. Market RWE will facilitate escape from earlier stages of the small cell lung.

Growth Drivers

• Technological developments in biomarker platforms provide the potential for more accurate and comprehensive knowledge of tumor immunobiology. Multiple IHC, NGS-based testing to detect gene mutations and gene expression profiles, epigenetic mapping to define higher-order gene structures, and metabolic profiling to assess the tumor's energy status are among the quickly expanding fields of biomarker research in the immuno-oncology market. Combining these methods can offer a comprehensive depiction of the tumor from multiple perspectives. When multiple IHC and imaging are combined with NGS, for instance, the spatial distribution of gene expression in the context of cell-cell interactions inside the tumor may be revealed.
• Anti-PD-(L)1 and anti-CTLA-4 immunotherapy has changed cancer treatment in the immuno-oncology market, although resistance and toxicity persist. New immunoregulatory targets and mechanisms are being discovered as I-O advances, promising to enhance therapeutic immunotherapy. As cancer immunobiology is better understood and antibody engineering advances, agents targeting additional inhibitory immune checkpoints, such as LAG-3, TIM-3, TIGIT, CD47, and B7 family members, are becoming important in cancer immunotherapy research.
• Precision medicine methods such as immunotherapy and molecularly targeted treatment have changed cancer care within the immuno-oncology clinical trials market. However, few people benefit from these therapies. Most cancers develop resistance to conventional treatments. These issues are being addressed by clinical studies of various treatment combinations. These studies use immunotherapy, molecularly targeted therapy, and radiation to treat different malignancies. There is emerging evidence that combination treatment may prevent or delay resistance. When combined with other cancer treatments, immunotherapies, especially ICIs, are effective. Multiple FDA approvals of immunotherapy combinations for cancer therapy are indicative of their effectiveness in the next-generation immuno-oncology therapies market.
• There is a need for wider adoption of innovative tools that can effectively measure and integrate the various host factors that influence tumor immunity and the response to immunotherapy in the immuno-oncology market. Wearable devices can track various physiologic variables, including heart rate, respiratory rate, oxygenation levels, sleep patterns, and stress and distress levels. Instruments for assessing systemic inflammation and metabolic fitness are either under development or commercially accessible. Tools are available to capture consumption of food and other metabolites to describe metabolic variables within the adaptive AI-driven oncology trials market. Technology is available to describe dietary patterns and examine associations with outcomes based on data.

Growth Restraints

• Three significant challenges exist when it comes to understanding the mechanisms of antitumor response, immune-related toxicity, and therapeutic resistance: the ability to use tumor models that are relevant to clinical applications for both forward and reverse translation; the availability of biospecimens collected from patients undergoing immunotherapy treatment, allowing for longitudinal analysis at baseline, during treatment, and post-treatment; and the implementation of standardized definitions and frameworks for conducting studies in the immuno-oncology clinical trials market.
• Genomic testing has the potential to provide valuable clinical information in the immuno-oncology market, but it can also have financial and psychological consequences for individuals and families. It may also lead to social stigma and affect one's ability to obtain insurance. Testing can be challenging due to the need for fast testing and efficient data analysis. Another problem with clinical follow-up is the need for reevaluating the danger to a family and an individual when new germline pathogenic variations are identified, and their relative risk of illness is determined.
• Identifying the most suitable antigens to target within the immuno-oncology biomarker platforms market continues to be a significant challenge. Tumors caused by viral infection or genetic mutations, whether inherited or acquired, may contain (neo)antigens that the immune system can easily identify. In other circumstances, common tumor antigens can provide a more widely applicable treatment. Examining premalignant lesions for new and powerful antigens to focus on is crucial in the context of the immuno-oncology market. Lesions that appear in the initial stages of tumorigenesis, such as hyperplasia and carcinoma in situ, are typically tiny and offer only a small amount of tissue for examination. Accessing these lesions can be challenging and may require specialized procedures, such as colony cytology or bronchoscopy, performed by skilled professionals to obtain tissue samples.
• Preclinical models fall short in reproducing the effects of the interactions between the host environment and the onset, progression, and immune response of cancer in the adaptive AI-driven oncology trials market. This might partially account for their inadequacies in determining the mechanisms of immunotherapy response and resistance as well as immune-related toxicity. The community requires new models that can effectively capture the intricate interactions between the host and environment, which play a crucial role in shaping the dynamics between the tumor and immune system within the immuno-oncology market. For instance, breaking in the genetic smoke has been shown to enhance and change the developing tumors in cancers. In line with this, there is a definite correlation between the existence of a genomic smoking signature, particular smoking-related genetic alterations found by NGS and reflected by TMB, and the impact these have on immune cell behavior in the context of cancer in the immuno-oncology clinical trials market. There is still much to be discovered regarding the indirect environmental exposures on tumor immunity and the effectiveness of immunotherapy.

Table of Contents

Research Scope

• Market Definition, Scope, and Segmentation
• Market Segmentation

Growth Environment: Transformation in the I-O Therapeutics Market

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the I-O Therapeutics Industry

Ecosystem in the I-O Therapeutics Market

• Cancer Cases and Deaths Worldwide
• Predicted Number of New Cancer Cases Worldwide
• Top Therapeutic Categories
• Oncology Drug Development Trend
• I-O Drug Development Trends
• Clinical Trial Challenges and Strategies to Overcome
• Technology Trends Across the Cancer Continuum
• I-O Business Models
• Strategic Partnerships and Collaborations-ICIs
• Strategic Partnerships and Collaborations-ACT
• Strategic Partnerships and Collaborations-Antibody-based Targeted Therapies
• Strategic Partnerships and Collaborations-Cancer Vaccines
• Key Strategies for Advancing Precision Oncology
• M&A Assessment
• Venture Financing Assessment
• Competitive Environment
• Key Competitors: I-O Value Chain and Stakeholder Ecosystem

Growth Generator in I-O Therapeutics Market

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Research Process and Methodology
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Modality
• Revenue Forecast Analysis
• Revenue Forecast by Indication
• Revenue Forecast Analysis
• Revenue Forecast by Region
• Forecast Analysis by Region
• Trends and Initiatives-North America
• Trends and Initiatives-Europe
• Trends and Initiatives-APAC
• Trends and Initiatives-LATAM
• Trends and Initiatives-MENA
• I-O Pricing Trends and Potential Avenues for Cost Reduction
• Cancer Immunotherapy Cost Reduction Strategies in LMICs
• Revenue Share
• Revenue Share Analysis

Growth Generator: ICI

• Growth Metrics
• Revenue Forecast
• Forecast Analysis

Growth Generator: ACT

• Growth Metrics
• Revenue Forecast
• Forecast Analysis

Growth Generator: Antibody-based Targeted Therapies

• Growth Metrics
• Revenue Forecast
• Revenue Forecast-ADC

Growth Generator: Others

• Growth Metrics
• Revenue Forecast
• Forecast Analysis

Growth Opportunity Universe

• Growth Opportunity 1: Expanding the Use of Immune Checkpoint ICIs in Neoadjuvant and Pre-operative Settings for Early-Stage Cancer
• Growth Opportunity 2: Advancing Multi-biomarker Approaches
• Growth Opportunity 3: Preclinical Models That Precisely Mimic Tumor Immunobiology
• Growth Opportunity 4: Generative AI-based In Silico Techniques

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer